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Abstract 
Background: Since treatment for latent cryptococcal infection (CI) before starting antiretroviral therapy (ART) 
reduces mortality in HIV-infected subjects, screening for cryptococcal antigen (CrAg) in blood is recommended for 
individuals with CD4 cell counts < 100 cells/µL in regions with high CI prevalence. We assessed CrAg screening using 
the lateral flow assay in HIV-infected adults eligible for ART in central Ethiopia.
Results: HIV-positive patients (age ≥ 18 years, CD4 cell count < 350 cells/μL and/or WHO stage IV, no current or 
previous ART) were recruited at Adama Regional Hospital, Ethiopia (February 2013 until March 2014). CrAg was 
determined in plasma by lateral flow assay. Among 129 included participants (median age 35 years, 64 % female) the 
median CD4 cell count was 210 cells/μL (interquartile range 110–309); 29 (23 %) had CD4 cell count < 100 cells/μL. 
Two (1.6 %) participants were CrAg-positive (CD4 cell counts 171 vs. 250 cells/µL), one of whom had clinically manifest 
cryptococcal meningitis at the time of testing.
Conclusions: In contrast to two recent reports from Ethiopia, we found few cases of CI among ART-naïve adults. Our 
study, which is the first using lateral flow assay for CrAg screening in this country, illustrates the need of larger surveys 
of CI prevalence among ART-naïve patients before defining recommendations on CI screening.
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Findings
Cryptococcal infection (CI) is a major cause of disease 
and death among HIV-infected individuals, with the 
highest case burden in sub-Saharan Africa [1]. Despite 
increasing access to antiretroviral therapy (ART), mor-
tality by cryptococcal meningitis (CM) remains high [1], 
partly explained by unmasking of latent CI in individuals 
with advanced immunosuppression at ART initiation [2]. 
The presence of cryptococcal antigen (CrAg) in blood is 
strongly associated with subsequent mortality after start-
ing ART [3]. Administration of pre-emptive fluconazole 
therapy to CrAg-positive patients before starting ART 
has been shown to reduce the incidence of CM [4]. For 
this reason, the World Health Organization (WHO) rec-
ommends CrAg screening in ART-naïve persons with 
CD4 cell counts <100 cells/µl in regions with high preva-
lence of cryptococcal antigenemia [5].
CM is known to occur in Ethiopia, but the magnitude 
of this disease is unclear. Recently, two cross-sectional 
studies reported high prevalence of cryptococcal anti-
genemia, both in ART-naive subjects and in patients 
receiving ART [6, 7].
Here, we present findings of an assessment of CI 
screening using the lateral flow assay in ART-naïve 
patients at a large public ART clinic in Central Ethiopia.
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 Methods
Participants were recruited at the ART outpatient clinic 
at Adama Regional Hospital, Adama. HIV-positive sub-
jects fulfilling criteria for ART initiation at the time of the 
study (CD4 cell count < 350 cells/μL and/or WHO stage 
IV) were eligible for inclusion. Additional inclusion cri-
teria were: age ≥ 18 years, no current or previous ART, 
residence in the catchment area and written informed 
consent. Inclusion lasted from February 26 2013 until 
March 8 2014. The study received ethical approval from 
the ethical review boards at Lund University, Sweden, 
and the Federal Institute for Science and Technology, 
Addis Ababa, Ethiopia.
Study nurses collected demographic and clinical data 
(including physical examination) at inclusion, follow-
ing a structured questionnaire. CD4 cell count, com-
plete blood count and CrAg testing was performed at 
the Adama Regional Laboratory. Determination of CrAg 
was done on plasma and cerebrospinal fluid (if available), 
using the IMMY CrAg LFA (Immuno-Mycologics Ink, 
Norman, OK), following the manufacturer’s instructions. 
In case of clinically suspected CM and/or other serious 
conditions, a physician in the clinic (TY) was consulted. 
Lumbar puncture was performed for all patients with 
suspected meningitis. The outcome of participants was 
assessed through clinic registers at the end of the study.
Results and discussion
Baseline characteristics of the 129 included subjects are 
shown in Table 1. Two (1.6 %) patients were CrAg-positive. 
The first case was a 38-year old woman (CD4 cell count 
171 cells/μL) who presented with headache, cough, dysp-
noea, constitutional symptoms and neck stiffness. Lumbar 
puncture showed meningitis with detectable CrAg. Despite 
fluconazole treatment she died 17 days after diagnosis. The 
second case was a 38-year old man (CD4 cell count 250 
cells/μL); at the time of testing he did not show any clinical 
symptoms or signs compatible with cryptococcosis.
None of the participants were diagnosed with cryp-
tococcosis during follow-up. At the end of the study, 96 
(74.4  %) of participants remained in care. One (0.8  %) 
death was reported; 6 (4.7  %) patients had been trans-
ferred to other health facilities, whereas 26 (20.2 %) were 
lost to follow-up.
Management of common and severe opportunistic 
infections is a critical component of HIV care. CI screen-
ing in subjects starting ART may improve treatment out-
come, but the indication for screening depends on the 
prevalence of CI in different settings. In our study pop-
ulation the prevalence of CI was low. In particular, only 
one case of asymptomatic CI was detected; the other 
CrAg-positive subject had clinically apparent meningitis 
at presentation.
Our findings differ from those presented in two recent 
reports from Ethiopia [6, 7], one of which was based in 
the same uptake area as our investigation [7]. In contrast 
to ours, both these studies included large proportions 
of patients receiving ART (271/369 [74  %] and 127/254 
[50  %], respectively, [6, 7]). Furthermore, we performed 
CrAg testing using the lateral flow assay. Although both 
latex agglutination and lateral flow assays have high 
specificity, the lateral flow assay has higher sensitivity, 
and is preferred for field use since it is cheaper, requires 
less equipment and does not require refrigeration [5, 8]. 
Compared to the agglutination assay, which was used in 
the previous Ethiopian studies, the lateral flow assay can 
be performed as a point-of-care test. Evaluations of the 
lateral flow assay show excellent performance [9]. There-
fore we consider false-negative reactions unlikely; this 
is further supported by the absence of incident cases of 
cryptococcal disease following ART initiation in our 
participants. Apart from differences with regard to ART 
Table 1 Baseline characteristics of included participants
IQR interquartile range, BMI body-mass index, MUAC mid-upper arm 
circumference
Data presented as n (%), if not stated otherwise
Total (n = 129)
Age, median (IQR) 35 (28–39)
Female gender 83 (64)
Pregnant, n (% of females) 1 (1)
Rural residence 18 (11)
BMI—kg/m2, median (IQR) 20 (18–22)
MUAC—cm, median (IQR) 23 (21–26)
CD4 cell count—cells/μL, median (IQR) 210 (110–309)
CD4 cell count <100 cells/μL 29 (23)
CD4 cell count <200 cells/μL 57 (45)
Hemoglobin—g/dL, median (IQR) 12 (11–13)
Study nurse investigations
 Currently diagnosed with TB 6 (5)
 WHO HIV disease stage
 1–2 58 (47)
 3 60 (48)
 4 6 (5)
 Neck stiffness 4 (3.2)
 Neurologic deficit 0 (0)
 Confusion 0 (0)
Self-reported symptoms
 Fever 48 (37.5)
 Night sweat 41 (32.3)
 Weight loss 58 (45.0)
 Fatigue 50 (40.3)
 Cough 33 (25.6)
 Diarrhea 19 (14.7)
 Headache 64 (49.6)
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status and degree of immunosuppression, geographical 
and health facility factors could explain the discordant 
rates of CI found in these three Ethiopian studies. Inter-
estingly, Alemu et  al. noted significantly higher preva-
lence of CI in one of two study sites in the Addis Ababa 
area [6], suggesting that the rate of CI can vary greatly 
even within the same region. The two cases of CI that 
occurred in our population were found in persons with 
CD4 cell counts > 100 cells/µL. This finding supports the 
results reported by Beyene et al. [7], illustrating that CI 
can occur also in persons with CD4 cell counts above the 
threshold level in current screening recommendations.
Our study does not corroborate previous reports 
of high rates of CI in Ethiopian HIV-infected adults. 
Although CI screening has been shown to be cost-effec-
tive in regions with CI prevalence above 3  % [3], each 
decision to implement any simple screening procedure 
in HIV programs in resource-limited settings may cause 
other initiatives not to be undertaken. Therefore, it is cru-
cial that decisions on management guidelines are based 
on broad and well-documented basis. In our opinion, 
larger studies of treatment-naïve persons from different 
geographical regions of Ethiopia, and with comparison of 
diagnostic methods, are required before definite guide-
lines on testing and management of CI can be issued.
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